科研速览 · Science Skim继续刷下去 · Keep skimming →
◆ Patient related outcome measures2026-01-01

Content validity of the Familial Chylomicronemia Syndrome Symptoms and Impacts Scale (FCS-SIS) for severe hypertriglyceridemia (sHTG).

Asia Sikora Kessler, Tammy Michelle Brown, Bonita Basnyat, Aaron Yarlas, Jennifer Dine

一句话结论 · In one sentence

FCS-SIS symptom items are content-valid items for the assessment of sHTG symptoms in adults with sHTG.

原始摘要(英文原文)· Original abstract
OBJECTIVE: Severe hypertriglyceridemia (sHTG) and familial chylomicronemia syndrome (FCS) are metabolic conditions associated with an increased risk of adverse health outcomes. The FCS Symptoms and Impacts Scale (FCS-SIS) was developed to assess the symptoms and impacts of FCS. This study assessed the content validity of the 4 FCS-SIS symptom items in adults with sHTG. METHODS: Two iterative rounds of qualitative interviews were conducted with adults (aged ≥ 18 years) who had clinician-confirmed sHTG (triglycerides ≥ 500 mg/dL) and recently experienced ≥ 2 symptoms of sHTG. Participants described their initial experiences and symptoms of sHTG during concept elicitation. Cognitive debriefing of the 4 FCS-SIS symptom items assessed relevance, interpretability, answerability, and meaningful change. RESULTS: Among 20 participants, the most frequently reported, most bothersome, and most important-to-treat sHTG symptoms were difficulty thinking (n = 20), physical fatigue (n = 20), diarrhea (n = 19), and abdominal pain (n = 18), which the 4 FCS-SIS symptom items assess. Participants reported these items to be easy to understand (n = 20) and, for most items, reported that a 1- to 2-point improvement would be meaningful. CONCLUSION: FCS-SIS symptom items are content-valid items for the assessment of sHTG symptoms in adults with sHTG.
读原文 · Read the paper ↗

AI 追问PRO

登录后使用 AI 追问

讨论区

登录后参与讨论

相关论文 · Related

Content validity of the Familial Chylomicronemia Syndrome Symptoms and Impacts Scale (FCS-SIS) for severe hypertriglyceridemia (sHTG). — 科研速览 Science Skim